Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

Abstract: Methods and apparatus for controlling a bias voltage supplied to an optical modulator, the modulator comprising a biasable component, the biasable component being configurable to be biased by application of the bias voltage (20) such that the modulator operates at quadrature, the method comprising: providing a target for the output power of the modulator, the target for the output power of the modulator being an output power corresponding to the modulator operating at quadrature; applying, to the biasable component, a bias voltage (20) having an initial value of 0V; and, thereafter, varying the bias voltage (20) until the value of the bias voltage (20) is the value that is closest to the initial value and that biases the biasable component so that the output power of the modulator is within a pre-defined range of the target output power.

Abstract: Various embodiments relating to using motion based view matrix tuning to calibrate a head-mounted display device are disclosed. In one embodiment, the holograms are rendered with different view matrices, each view matrix corresponding to a different inter-pupillary distance. Upon selection by the user of the most stable hologram, the head-mounted display device can be calibrated to the inter-pupillary distance corresponding to the selected most stable hologram.

Abstract: In one embodiment of the invention a catheter (203) comprises a body having at least one inlet aperture (21, 24), at least one outlet aperture (22, 25), and at least one passage (20, 23) between the at least one inlet aperture (21, 24) and the at least one outlet aperture (22, 25). The catheter (203) is provided with pumping means (32) for selectively pumping fluid from one of said apertures (21, 22, 24, 25) to another of said apertures (21, 22, 24, 25). Methods of operating such a catheter are also disclosed.

Abstract: Embodiments are described herein for determining a stabilization plane to reduce errors that occur when a homographic transformation is applied to a scene including 3D geometry and/or multiple non-coplanar planes. Such embodiments can be used, e.g., when displaying an image on a head mounted display (HMD) device, but are not limited thereto. In an embodiment, a rendered image is generated, a gaze location of a user is determined, and a stabilization plane, associated with a homographic transformation, is determined based on the determined gaze location. This can involve determining, based on the user's gaze location, variables of the homographic transformation that define the stabilization plane. The homographic transformation is applied to the rendered image to thereby generate an updated image, and at least a portion of the updated image is then displayed.

Abstract: A system and method are disclosed for detecting angular displacement of a display element relative to a reference position on a head mounted display device for presenting a mixed reality or virtual reality experience. Once the displacement is detected, it may be corrected for to maintain the proper binocular disparity of virtual images displayed to the left and right display elements of the head mounted display device. In one example, the detection system uses an optical assembly including collimated LEDs and a camera which together are insensitive to linear displacement. Such a system provides a true measure of angular displacement of one or both display elements on the head mounted display device.

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

Abstract: The present invention provides an electrolyte component containing one or more salts including lithium bis(oxalate)borate (LiBOB), a solvent, propylene carbonate (PC) and a crystallizable polymer wherein said LiBOB is present as a weight percentage of 0.5% or more, said propylene carbonate is present as a weight percentage of between 5% and 90% and the crystallizable polymer is present at a weight percentage of greater than 1%. It also provides a galvanic cell formed from the above and a process for forming same.

Abstract: Various embodiments relating to using motion based view matrix tuning to calibrate a head-mounted display device are disclosed. In one embodiment, the holograms are rendered with different view matrices, each view matrix corresponding to a different inter-pupillary distance. Upon selection by the user of the most stable hologram, the head-mounted display device can be calibrated to the inter-pupillary distance corresponding to the selected most stable hologram.

Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: A head-mounted display device is disclosed, which includes an at least partially see-through display, a processor configured to detect a physical feature, generate an alignment hologram based on the physical feature, determine a view of the alignment hologram based on a default view matrix for a first eye of a user of the head-mounted display device, display the view of the alignment hologram to the first eye of the user on the at least partially see-through display, output an instruction to the user to enter an adjustment input to visually align the alignment hologram with the physical feature, determine a calibrated view matrix based on the default view matrix and the adjustment input, and adjust a view matrix setting of the head-mounted display device based on the calibrated view matrix.

Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

Abstract: A graphics processing system for processing polygons includes a cache with cache lines for storing data entries, each line having a tag for identifying the data stored in the line. The polygons have vertices with which pieces of vertex attribute data are associated. The system also includes processing circuitry which writes, to a line in a first set of lines, data entries associated with pieces of vertex attribute data. The pieces of vertex attribute data are associated with the vertices of a polygon. The processing circuitry also writes a tag including a polygon identifier to identify the polygon associated with the data entries to the line in the first set of lines, and writes, to a second set of lines of the cache, data entries associated with pieces of vertex attribute data. The processing circuitry also writes tags including vertex identifiers to the second set of lines to identify the vertices associated with the data entries.

Abstract: According to a first aspect of the present invention, there is provided a duplexer for a radio frequency antenna, comprising: a radio frequency signal transmitter port arranged for connection to a radio frequency signal transmitter; a radio frequency signal receiver port arranged for connection to a radio frequency signal receiver; a switch arranged selectively to adopt either one of: a first state which connects the transmitter port to a common input/output port of the switch arranged for connection to a radio frequency antenna; and a second state which connects the receiver port to the common input/output port; a switch control unit arranged to monitor radio frequency power at the common input/output port and to receive a transmission gate signal; wherein the switch control unit is arranged to control the switch to adopt the first state upon receipt of the transmission gate signal, and, subsequently, to control the switch to adopt the second state when the monitored radio frequency power falls below a thres

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

Abstract: Methods and apparatus for finding a bias voltage (20) corresponding to a quadrature point of an optical modulator, the modulator comprising a biasable component which is configurable to be biased by application of the bias voltage (20) such that the modulator operates at quadrature, the method comprising: providing a target for the output power of the modulator which corresponds to quadrature; applying, to the biasable component, a bias voltage (20) having an initial value; thereafter, finding a value for the bias voltage (20) that biases the biasable component such that the output power of the modulator is within a pre-defined range of the target by, starting at the initial value, alternately increasing and decreasing (or decreasing and increasing) the bias voltage (20) with gradually increasing amplitude; and identifying the found value for the bias voltage (20) as a bias voltage corresponding to a quadrature point of the optical modulator.

Abstract: The present document describes vehicle components. More specifically, the present document describes vehicle components such as fuel tanks, radiators, pedal box assemblies, reverse transmission systems and electronic control modules for a vehicle.

Abstract: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.